.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AE04_Ponesimod.Ponesimod

Information

Ponesimod is a selective sphingosine 1-phosphate receptor-1 (S1P1) modulator approved for the treatment of relapsing forms of multiple sclerosis (MS) in adults. It reduces lymphocyte egress from lymph nodes, thereby decreasing inflammatory activity in MS.

Pharmacokinetics

Pharmacokinetic parameters are reported in healthy adult subjects after single oral doses.

References

1. Kruger, TM, et al., & Ruixo, JJP (2023). Clinical Pharmacokinetics of Ponesimod, a Selective S1P1 Receptor Modulator, in the Treatment of Multiple Sclerosis. Clinical pharmacokinetics 62(11) 1533–1550. DOI:10.1007/s40262-023-01308-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37776485

2. Baldin, E, & Lugaresi, A (2020). Ponesimod for the treatment of relapsing multiple sclerosis. Expert opinion on pharmacotherapy 21(16) 1955–1964. DOI:10.1080/14656566.2020.1799977 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32808832

3. Reyes, M, et al., & Dingemanse, J (2014). Effects of ethnicity and sex on the pharmacokinetics and pharmacodynamics of the selective sphingosine-1-phosphate receptor 1 modulator ponesimod: a clinical study in Japanese and Caucasian subjects. Pharmacology 94(5-6) 223–229. DOI:10.1159/000368837 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25402365

Revisions

• 06/2025 initial generated model